New radioactive therapy shows promise for Hard-to-Treat cancers
NCT ID NCT07587996
First seen May 16, 2026 · Last updated May 23, 2026 · Updated 3 times
Summary
This early-phase study tested a new radioactive drug called 177Lu-CTR-FAPI in 12 people with advanced solid tumors (breast, sarcoma, thyroid) that had spread and no longer responded to standard treatments. The main goal was to check if the drug is safe and how it spreads in the body. Researchers also looked for early signs that the drug might shrink tumors. This is a first step to see if further testing is worthwhile.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMORS (ANY LOCALIZATION) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Second Hospital & Clinical Medical School, Lanzhou University
Lanzhou, Gansu, 730000, China
Conditions
Explore the condition pages connected to this study.